当前位置: 首页 > 师资队伍 > 教授 > 微生物学与免疫学系 > 正文
师资队伍

微生物学与免疫学系

张海红

日期:2020-08-11 点击数: 来源:


张海红


姓名: 张海红
职称: 教授
最高学位: 博士
电话:
Email:
工作地点: 生命科学楼413室


研究方向: 肿瘤免疫治疗 肿瘤疫苗研究
教育经历: 1999.9-2003.7 吉林师范大学生命科学学院 本科
2003.9-2006.7 吉林大学生命科学学院     硕士
2006.9-2009.7 吉林大学生命科学学院     博士
工作经历: 2009.07-2012.09 吉林大学生命科学学院艾滋病疫苗国家工程实验室 讲师
2012.10-2017.12 吉林大学生命科学学院艾滋病疫苗国家工程实验室 副教授
2017.10-现在    吉林大学生命科学学院艾滋病疫苗国家工程实验室 教授(评完待聘)
荣誉称号: 第五届吉林省大学生生命科学创新实验大赛中,荣获指导教师二等奖。

研究成果: 代表性文章
1. Fang-Fang Zhang, Yu Xie, Qianqian Guo, Ping Xu, Chenlu Liu, Fei Geng, Zhenzhen Lu, Hui Wu, Bin Yu, Jia-Xin Wu, Wei Kong, Xiang-Hui Yu, Hai-Hong Zhang*. Epitope-based minigene vaccine targeting fibroblast activation protein α can induce specific immune responses and anti-tumor effects in the 4T1 murine breast cancer model,vaccine,Minor Revision.
2. Chenlu Liu, Zhenzhen Lu, Yu Xie Qianqian Guo, Fei Geng, Bo Sun, Hui Wu, Bin Yu, Jiaxin Wu, Xianghui Yu, Wei Kong, Haihong Zhang*. Soluble PD-1-based vaccine targeting MUC1 VNTR and survivin improves anti-tumor effect. Immunology letter. Under Review.
3. Chenlu Liu, Yu Xie, Bo Sun, Fei Geng, Fangfang Zhang, Qianqian Guo, Hui Wu, Bin Yu, Jiaxin Wu, Xianghui Yu, Wei Kong, Haihong Zhang*. MUC1- and survivin - based DNA vaccine combining immunoadjuvants CpG and interleukin 2 in a bicistronic expression plasmid generates specific immune responses and anti-tumor effects in a murine colorectal carcinoma model. Scand J Immunol.2018 Feb; 87 (2):63-72.
4. Qiu Xia, Fei Geng, Fang-Fang Zhang, Chen-Lu Liu, Ping Xu, Zhen-Zhen Lu, Yu Xie, Hui Wu,Bo Sun, Wei Kong, Xiang-Hui Yu, Hai-Hong Zhang*. Cyclophosphamide enhances anti-tumor effects of a fibroblast activation protein α-based DNA vaccine in tumor-bearing mice with murine breast carcinoma. Immunopharmacol Immunotoxicol. 2017 Feb;39(1):37-44.
5. Qiu Xia, Fang-Fang Zhang, Fei Geng, Chen-Lu Liu, Yu-Qian Wang, Ping Xu, Zhen-Zhen Lu, Yu Xie, Hui Wu, Yan Chen, Yong Zhang, Wei Kong, Xiang-Hui Yu, Hai-Hong Zhang*, Improvement of anti-tumor immunity of fibroblast activation protein a based vaccines by combination with cyclophosphamide in a murine model of breast cancer. Cellular Immunology. 2016 Dec; 310:89-98.
6. Qiu Xia, Fei Geng, Fang-Fang Zhang, Chen-Lu Liu, Ping Xu, Zhen-Zhen Lu, Bin Yu, Hui Wu, Jia-Xin Wu, Hai-Hong Zhang*, Wei Kong, Xiang-Hui Yu Enhancement of FAPα-targeted immunotherapy and adenovirus boost immunity by cyclophosphamide through inhibiting IL-10 expression in 4T1 tumor bearing mice. Vaccine. 2016 Aug 31; 34(38): 4526-35. doi: 10.1016/j. vaccine. 2016.07.054..
7. Haihong Zhang, Chenlu Liu, Qiu Xia, Zhenzhen Lu, Ping Xu, Fangfang Zhang, Fei Geng, Hui Wu, Bin Yu, Jiaxin Wu, Xianghui Yu*, and Wei Kong*,MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model. Vaccine. 2016 May 23; 34(24):2648-55.
8. Qiu Xia, Fang?Fang Zhang, Fei Geng, Chen?Lu Liu, Ping Xu, Zhen?Zhen Lu, Bin Yu, Hui Wu, Jia?Xin Wu, Hai?Hong Zhang*, Wei Kong, Xiang?Hui Yu. Anti?tumor effects of DNA vaccine targeting human fibroblast activation protein αby producing specific immune responses and altering tumor microenvironment in the 4T1 murine breast cancer model. Cancer Immunology, Immunotherapy. 2016 May; 65(5):613-24.
9. YuQian Wang, Chenlu Liu, Qiu Xia, Wang Peng, Bo Li, Zhenzhen Lu, Jiaxi Sun, Hui Wu, Bin Yu, Jiaxin Wu, Xianghui Yu, Wei Kong, HaiHong Zhang* and Xianling Cong*. Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs. Oncol Rep. 2014 Mar;31(3):1437-44.
10. Hui Wu#, Haihong Zhang#, Yue Hu, Qiu Xia, Chenlu Liu, Yingnan Li, Bin Yu, Tiejun Gu, Xizhen Zhang, Xianghui Yu,* and Wei Kong,*.Sphere Formation Assay is Not an Effective Method for Cancer Stem Cell Derivation and Characterization from the Caco-2 Colorectal Cell Line. Curr Stem Cell Res Ther. 2014 Mar; 9(2):82-8.
11. Hui Wu,? Haihong Zhang,? Peng Wang, Zhuo Mao, Li Feng, Yuqian Wang, Chenlu Liu, Qiu Xia, Bo Li, Heya Zhao, Yan Chen, Jiaxin Wu, Wei Kong,* Xianghui Yu*,Short-Form CDYLb but not long-form CDYLa functions cooperatively with histone methyltransferase G9a in hepatocellular carcinomas. Genes Chromosomes Cancer. 2013 Jul; 52(7):644-55.
12. Yu-Qian Wang1, Hai-Hong Zhang1, Chen-Lu Liu, Hui Wu, Peng Wang, Qiu Xia, Li-Xing Zhang, Bo Li, Jia-Xin Wu, Bin Yu, Tie-Jun Gu, Xiang-Hui Yu*, Wei Kong*. Enhancement of survivin-specific anti-tumor immunity by adenovirus prime protein-boost immunity strategy with DDA/MPL adjuvant in a murine melanoma model. International Immunopharmacology.  2013 Apr 25; 17(1):9-17.
13. Yu-Qian Wang&, Hai-Hong Zhang&, Chen-Lu Liu, Qiu Xia, Hui Wu, Xiang-Hui Yu*, Wei Kong*. Correlation between auto-antibodies to survivin and MUC1 VNTR in colorectal cancer. Asian Pacific Journal of Cancer Prevention. 2012, 13: 5557-62.
14. Haihong Zhang, Yuqian Wang, Chenlu Liu, Lixing Zhang, Qiu Xia, Yong Zhang, Jiaxin Wu, Chunlai Jiang, Yan Chen, Yongge Wu, Xiao Zha, Xianghui Yu* and Wei Kong*. DNA and Adenovirus Tumor Vaccine Expressing Truncated Survivin Generates Specific Immune Responses and Antitumor Effects in a Murine Melanoma Model. Cancer Immunology Immunotherapy. 2012,61:1857–1867(2012-09-24)
15. ZHANG Li-xing, DU Jian-shi, WANG Yu-qian, LIU Chen-lu, XIA Qiu, ZHANG Xi-zhen, Yu Xiang-hui, Kong Wei, CONG Xian-ling, ZHANG Hai-hong*, Establishment of a Tumor-bearing Mouse Model Stably Expressing Human Tumor Antigens Survivin and MUC1 VNTR. Chemical Research In Chinese Universities, 2012, 28(2), 259-263.
主持、参与或执行的科研项目:
1. “十三五”国家科技重大专项,2018ZX09301050-003、创新肿瘤治疗性疫苗的研发、2018/06-2020/12、183.85万元、主持;
2. 吉林省科技处,20160519018JH、吉林省新型肿瘤疫苗研究创新团队、2016.01-2018.12,20万元、参与、在研;
3. “十二五”国家科技重大专项,2014ZX09304314-001、以survivin和MUC1为靶点重组腺病毒载体肿瘤治疗性疫苗的临床前研究、164.47万、执行、已结题;
4. 国家自然基金青年项目,31300765、以 MUC1 VNTR、survivin和FAP-α为靶点的自组装纳米载体基因疫苗抗肿瘤作用机制研究、2014/01-2016/12、23万元、主持、已结题;
5. 长春百克生物科技股份公司、肿瘤治疗性疫苗的研究、2012-2019、120万元、主持、在研,
6. 吉林省科技发展计划,20130522006JH、双基因自组装纳米载体肿瘤疫苗研究、2013.01-2015.12、3万元、主持、已结题;
7. 教育部新教师基金,20120061120025、针对肿瘤微环境及肿瘤细胞的三基因肿瘤疫苗作用机制研究、2013.01-2015.12、4万元、主持、已结题;
8. 吉林省产业技术研究与开发专项项目,2013C014-3、肺癌早期基因诊断技术的研究与开发、2013/01 - 2014/12、10万元、参与、已结题;
9. 吉林大学基本科研业务费,450060323260、以 survivin和MUC1 VNTRs 为靶点的肿瘤基因疫苗免疫佐剂的效果研究、2011/01-2012/12、2万元、主持、已结题;
10. 吉林大学交叉学科项目,200903255、以 survivin和MUC1 VNTRs 为靶点的肿瘤基因疫苗异源prime - boost免疫策略的研究、2009/12-2011/01、5万元、主持、已结题。
专利
1. 以粘蛋白1和生存素为靶点的肿瘤DNA疫苗和病毒载体疫苗(专利号:ZL200910252427.x),发明人:孔维;张海红;于湘晖;于永慧
授权日2015.01.07
2. 以粘蛋白1和生存素为靶点的肿瘤DNA疫苗及病毒载体疫苗-分案(申请号ZL201410189139.5),发明人:孔维;张海红;于湘晖;于永慧 授权日2016.08.03
3. 以粘蛋白1和生存素为靶点的肿瘤基因工程疫苗(申请号: ZL201110086366.1),发明人:孔维 张海红 于湘晖 于永慧 王玉倩 张丽星 授权日2016.4.20
4. 以成纤维激活蛋白α为靶点的肿瘤DNA疫苗及病毒载体疫苗(申请号:201610164451.8),发明人:张海红 于湘晖 孔维 夏秋 耿飞,
5. 以FAPα来源的抗肿瘤CTL表位肽FAP.291和模拟肽FAP.291I9为基础的肽类疫苗和微基因疫苗的应用(申请号:201711060548.5), 发明人:张海红、于湘晖、孔维、张芳芳、刘晨露、徐平、耿飞、谢雨、郭倩倩、陆臻桢